DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, Type of End User and Key Geographical Regions” has been added to ResearchAndMarkets.com’s offering.
The global cell therapy media market is projected to grow from USD 1.6 billion in the current year to USD 4.5 billion by 2035, with a CAGR of 11.1%. This growth is primarily driven by advancements and the confirmed efficacy of FDA-approved cell therapies for cancer, rare diseases, and chronic conditions. Over 1,000 clinical trials centered on cell therapies have been registered since 2019, with more than 35 therapies reaching the market. Recent approvals include Breyanzi, CarvyktiT, and Abecma.
Due to stringent regulations in producing cell therapy consumables, over 90% of developers outsource products like culture media and extracellular matrices to expert suppliers, with more than 80 companies offering over 450 types of raw materials. Many suppliers boast GMP-certified facilities catering to diverse cells, including T-cells and stem cells.
Innovation and partnerships in this realm are anticipated to rise, potentially transforming patient care and expanding regenerative medicine.
The report highlights several key industry insights:
- With over 450 kits, media, and reagents, providers cater to both research and therapeutic needs.
- Over 80 companies operate globally, predominantly emerging players from North America.
- The majority of available kits focus on reagents for stem cell therapies, with most stored refrigerated.
- Media is offered mainly in 100 to 500 ml volumes by nearly 90% of developers.
- Reagents serve a variety of discovery-scale functions, such as cell expansion.
- Matrices are well-distributed by ECM coating type and formulation, typically with 1 to 1.5 years of shelf life.
- Providers enhance technologies and expand portfolios to remain competitive.
- Strategic initiatives, including partnerships and expansions, bolster company capabilities.
- Cost considerations significantly influence consumable adoption in manufacturing processes.
The commercial scale of operation is expected to account for 75% of total demand by 2035, propelled by anticipated multiple therapy approvals. A transition from animal-based to animal component-free formulations and strict regulatory guidelines are likely to fuel the market, maintaining an annual growth rate of 11.1%.
By segmentation, extracellular matrices represent the fastest-growing product segment. T-cell therapy is anticipated to dominate the market, driven by the ongoing evaluation of NK cell therapies across numerous clinical studies. The commercial scale is predicted to drive market expansion, with industry players contributing significantly. North America holds the largest market share, though Latin America’s market is expected to grow rapidly.
Noteworthy players include BD Biosciences, Bio-Techne, CellGenix, Corning, and others. A report built on discussions with industry stakeholders offers extensive coverage on market segments, offering insights into market forecast, landscape, competitiveness, brand positioning, and partner collaborations.
Reasons to Buy the Report:
- Comprehensive market analysis with detailed revenue projections aids strategic decisions for established leaders and newcomers.
- Competitive landscape insights enable businesses to optimize positioning and strategy development.
- Provides understanding of market dynamics, vital for capitalizing on growth opportunities.
Additional Benefits:
- Complimentary PPT Insights and Excel Data Packs
- 15% Free Content Customization
- Report Walkthrough with the Research Team
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2025-2035 |
| Estimated Market Value (USD) in 2025 | $1.6 Billion |
| Forecasted Market Value (USD) by 2035 | $4.5 Billion |
| Compound Annual Growth Rate | 11.1% |
| Regions Covered | Global |
Key Topics Covered
1. PREFACE
- 1.1. Introduction
- 1.2. Key Market Insights
- 1.3. Scope of the Report
- 1.4. Research Methodology
- 1.5. Frequently Asked Questions
- 1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
- 3.1. Context and Background
- 3.2. Introduction to Cell Therapies
- 3.3. Comparison of Cell Therapies with Other Biopharmaceuticals
- 3.4. Classification of Cell Therapy Products
- 3.5. Overview of Cell Therapy Development and Manufacturing
- 3.6. Role of Raw Materials in Cell Therapy Development and Manufacturing
- 3.7. Types of Cell Therapy Consumables
- 3.8. Key Challenges Associated with Manufacturing of Cell Therapy Consumables
- 3.9. Future Perspectives
4. MARKET OVERVIEW
- 4.1. Chapter Overview
- 4.2. List of Cell Therapy Kit Providers
- 4.3. List of Cell Therapy Media Providers
- 4.4. List of Cell Therapy Reagent Providers
- 4.5. List of Cell Therapy Extracellular Matrix Providers
5. COMPANY COMPETITIVENESS ANALYSIS
- 5.1. Chapter Overview
- 5.2. Key Assumptions and Parameters
- 5.3. Methodology
- 5.4. Cell Therapy Consumables Providers: Company Competitiveness Analysis
- 5.5. Cell Therapy Kit Providers
- 5.6. Cell Therapy Media Providers
- 5.7. Cell Therapy Reagent Providers
- 5.8. Cell Therapy Extracellular Matrix Providers
6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
- 6.1. Chapter Overview
- 6.2. Scope and Methodology
- 6.3. Brand Positioning: STEMCELL Technologies
- 6.4. Brand Positioning: Miltenyi Biotec
- 6.5. Brand Positioning: Thermo Fisher Scientific
- 6.6. Brand Positioning: Takara Bio
- 6.7. Brand Positioning: GeminiBio
7. COMPANY PROFILES
- 7.1. Chapter Overview
- 7.2. STEMCELL Technologies
- 7.3. Miltenyi Biotec
- 7.4. Thermo Fisher Scientific
- 7.5. Bio-Techne
- 7.6. Irvine Scientific
- 7.7. Lonza
- 7.8. Sartorius
- 7.9. BD Biosciences
- 7.10. Corning
- 7.11. CellGenix
8. RECENT DEVELOPMENTS AND INITIATIVES
- 8.1. Chapter Overview
- 8.2. Partnership Models
- 8.3. Cell Therapy Consumables: Partnerships and Collaborations
- 8.4. Cell Therapy Consumables: Mergers and Acquisitions
- 8.5. Cell Therapy Consumables: Recent Expansions
9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS
- 9.1. Chapter Overview
- 9.2. Scoring Criteria and Key Assumptions
- 9.3. Scope and Methodology
- 9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
10. ROOTS ANALYSIS PRICING STRATEGY
- 10.1. Chapter Overview
- 10.2. Roots Analysis Pricing Strategy Framework
11. DEMAND ANALYSIS
- 11.1. Chapter Overview
- 11.2. Scope and Methodology
- 11.3. Global Demand for Cell Therapy Consumables
- 11.4. Analysis by Scale of Operation
- 11.5. Analysis by Geography
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
- 12.1. Chapter Overview
- 12.2. Key Assumptions and Methodology
- 12.3. Global Cell Therapy Consumables Market, Till 2035
- 12.4. Cell Therapy Consumables Market: Analysis by Type of Product
- 12.5. Cell Therapy Consumables Market: Analysis by Type of Cell Therapy
- 12.6. Cell Therapy Consumables Market: Analysis by Scale of Operation
- 12.7. Cell Therapy Consumables Market: Analysis by Type of End-User
- 12.8. Cell Therapy Consumables Market: Analysis by Geography
13. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
- 13.1. Chapter Overview
- 13.2. Emerging Trends Related to Cell Culture Media
- 13.3. Automation of Cell Therapy Manufacturing Processes
- 13.4. Single Use Systems and Technologies in Cell Therapy Manufacturing
14. CONCLUDING REMARKS
15. INTERVIEW TRANSCRIPTS
- 15.1. Chapter Overview
- 15.2. Company A
- 15.3. Company B
- 15.4. Company C
A selection of companies mentioned in this report includes, but is not limited to:
- Accellta
- Acer Therapeutics
- ACROBiosystems
- Activartis Biotech
- AddLife
- Adicet Bio
- Aduro Biotech
- Advanced BioMatrix (Acquired by BICO)
- Advent Bioservices
- AGC Biologics
- AgenTus Therapeutics
- Agilent Technologies
- Ajinomoto
- Akadeum Life Sciences
- Akron Biotech
- Allele Biotechnology and Pharmaceuticals
- Allife Medical Science and Technology
- Allogene Therapeutics
- Altor BioScience
- American CryoStem
- Amphera
- AMSBIO
- ANI Pharmaceuticals
- apceth Biopharma
- Applied Biological Materials
- Applied Cells
- Arbele
- Arcline Investment Management
- Argos Therapeutics
- Aspire Health Science
- Asterias Biotherapeutics
- ATCC
- Athersys
- Atlantis Bioscience
- Atreca
- Aurora Biopharma
- Austrianova
- Autolus
- Avantor
- AVAX Technologies
- Axion BioSystems
- Axol Bioscience
- and many more!
For more information about this report visit https://www.researchandmarkets.com/r/gsb1g0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900